StockData
ADMA Biologics, Inc. logo

ADMA Biologics, Inc. (ADMA) stock

ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3029% below fair value
$13.63+0.16 (+1.19%)

Close on Nov 17, 2026Market cap $3.05BP/E 19.5Yield –

ADMA Biologics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

ADMA Biologics's profit margin for the twelve months ending Jun 30, 2026 was 33.0%. For fiscal 2025 it was 28.8%, against 46.4% the year before. The highest annual figure on record is 46.4% in fiscal 2024.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202528.8%−17.6
FY2024Dec 31, 202446.4%+57.3
FY2023Dec 31, 2023-10.9%+31.8
FY2022Dec 31, 2022-42.8%+45.7
FY2021Dec 31, 2021-88.5%+90.9
FY2020Dec 31, 2020-179.4%−14.9
FY2019Dec 31, 2019-164.5%+222.6
FY2018Dec 31, 2018-387.1%−194.8
FY2017Dec 31, 2017-192.3%−9.2
FY2016Dec 31, 2016-183.1%+67.3
FY2015Dec 31, 2015-250.4%+33.9
FY2014Dec 31, 2014-284.2%+222.0
FY2013Dec 31, 2013-506.2%+146.8
FY2012Dec 31, 2012-653.0%+122.7
FY2011Dec 31, 2011-775.7%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202630.4%+2.4
Q1 FY2026Mar 31, 202639.6%+16.2
Q4 FY2025Dec 31, 202535.5%−59.7
Q3 FY2025Sep 30, 202527.1%−2.8
Q2 FY2025Jun 30, 202528.1%−1.9
Q1 FY2025Mar 31, 202523.4%+1.7
Q4 FY2024Dec 31, 202495.2%+119.1
Q3 FY2024Sep 30, 202430.0%+26.2
Q2 FY2024Jun 30, 202429.9%+40.5
Q1 FY2024Mar 31, 202421.7%+33.7
Q4 FY2023Dec 31, 2023-23.9%+0.6
Q3 FY2023Sep 30, 20233.8%+40.1
Q2 FY2023Jun 30, 2023-10.6%+30.0
Q1 FY2023Mar 31, 2023-11.9%+74.0
Q4 FY2022Dec 31, 2022-24.5%+38.6
Q3 FY2022Sep 30, 2022-36.3%+49.4
Q2 FY2022Jun 30, 2022-40.6%+65.4
Q1 FY2022Mar 31, 2022-85.9%+28.6
Q4 FY2021Dec 31, 2021-63.1%+76.0
Q3 FY2021Sep 30, 2021-85.7%+79.0
Q2 FY2021Jun 30, 2021-106.0%+153.1
Q1 FY2021Mar 31, 2021-114.5%+74.2
Q4 FY2020Dec 31, 2020-139.1%−51.3
Q3 FY2020Sep 30, 2020-164.6%−6.3
Q2 FY2020Jun 30, 2020-259.1%−57.7
Q1 FY2020Mar 31, 2020-188.7%+181.7
Q4 FY2019Dec 31, 2019-87.7%+356.9
Q3 FY2019Sep 30, 2019-158.4%+199.4
Q2 FY2019Jun 30, 2019-201.4%+115.3
Q1 FY2019Mar 31, 2019-370.3%+70.6
Q4 FY2018Dec 31, 2018-444.7%−336.5
Q3 FY2018Sep 30, 2018-357.8%−36.3
Q2 FY2018Jun 30, 2018-316.7%−50.9
Q1 FY2018Mar 31, 2018-440.9%−192.3
Q4 FY2017Dec 31, 2017-108.2%+28.8
Q3 FY2017Sep 30, 2017-321.5%−174.0
Q2 FY2017Jun 30, 2017-265.8%–
Q1 FY2017Mar 31, 2017-248.7%–
Q4 FY2016Dec 31, 2016-137.0%–
Q3 FY2016Sep 30, 2016-147.4%–

More ADMA Biologics figures

See a number that looks wrong?